Anti-BCR aptamer SELEX Service(Cat#: CTApt-1833)
This is an aptamer development services to screening aptamers binds to the BCR with an affinity of 1nM~1μM.
Specific Inquiry 
Specifications
| Target Category |
Protein |
| Target |
BCR |
| Alternative Names |
BCR Activator Of RhoGEF And GTPase; BCR, RhoGEF And GTPase Activating Protein; Breakpoint Cluster Region Protein; Renal Carcinoma Antigen NY-REN-26; Breakpoint Cluster Region; EC 2.7.11.1; D22S662; D22S11; BCR1; ALL; CML; PHL; BCR/FGFR1 Chimera Protei; FGFR1/BCR Chimera Protein; BCR |
| Gene ID |
613 |
| UniProt ID |
P11274 |
| Target Overview |
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The unregulated tyrosine kinase activity of BCR-ABL1 contributes to the immortality of leukaemic cells. The BCR protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac and other kinases. Two transcript variants encoding different isoforms have been found for this gene. |
| Chemical Modification |
N/A |
| Type |
DNA |
| Length |
20-80 nt |
| Affinity (Kd) |
1nM~1μM |
| Binding Conditions/Buffer |
PBS; buffer system with Serum; other |
For Research Use Only. Not for Diagnostic or Therapeutic Applications.
